 BOSTON, June 1, 2021 PRNewswire -- Stealth BioTherapeutics Corp Nasdaq: MITO, a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the European Medicines Agency EMA has granted orphan drug designation ODD for elamipretide for the treatment of Barth syndrome, an ultra-rare genetic condition. We are pleased that EMA has recognized, by granting ODD for elamipretide for Barth syndrome, the high unmet need for innovative treatments for this ultra-rare genetic condition, said Chief Executive Officer Reenie McCarthy. 